Company Overview: Edwards Lifesciences Corporation (NYSE: EW) is headquartered in Irvine, California. The company deals in products and technologies targeted at curing advanced cardiovascular diseases in critically unwell patients. The company is also one of the top players in hemodynamic monitoring systems, which is utilized to measure a patient's cardiovascular function in the hospital setting.
EW Details
Robust Product Adoption & Customer Additions Aid EW: Edwards Lifesciences Corporation (NYSE: EW) is one of the leading companies involved in focusing patient medical innovations for structural heart disease and serious care supervising. It is engaged in manufacturing of tissue heart valves and repair products, which are utilized to repair or replace patient's diseased or faulty heart valve. The company’s products and technologies are grouped into four key sections namely (1) Transcatheter Aortic Valve Replacement (TAVR), (2) Transcatheter Mitral and Tricuspid Therapies (TMTT), (3) Surgical Structural Heart, and (4) Critical Care. Despite COVID-19 led uncertainties, the company remains positive regarding the strong customer adoption of the TruWave disposable pressure monitoring devices. Further, the company is also optimistic regarding the demand for products used in cardiac surgeries, owing to the resumption of treatment in hospitals of non-COVID beings. These positives are likely to aid the financial performance of the company, going forward.
Looking at the past performance over the period of FY10-FY20, the company reported a CAGR of ~12.1% in total sales, with continuous upward progress. The below trend has been strongly backed by robust demand for heart valve surgery, strong adoption of the SAPIEN 3 Ultra platform along with positive cash flow from operations.
Key Trend (Source: Company Reports)
The company’s Surgical Structural Heart Group area is likely to see an upturn in business, as EW is witnessing recovery in surgical case volumes over the past few months. Further, patient’s willingness to obtain heart valve surgery and the hospitals being able to handle medical patient flow are few other positives. Coming to the TAVR arm, the company is likely to record improved worldwide sales on the back of strong adoption of the SAPIEN valve platform as well as recovery in procedure volumes. Strong customer adoption drives the momentum of the SAPIEN 3 Ultra platform. This, along with favorable clinician reaction on enhanced paravalvular leak implementation of the SAPIEN 3 Ultra, is expected to aid the top-line results, going forward. Despite pandemic related issues, robust adoption of TAVR outside the US is also expected to positively impact financial results.
4QFY20 Key Highlights: During the quarter, the company reported adjusted earnings per share of 50 cents, which went up 2% from the prior corresponding period. EPS on a GAAP basis increased ~11.4% year over year and came in at 44 cents per share. Net sales for 4QFY20 stood at $1.19 billion, depicting an increase of 1.5% on pcp. The rise in top-line can mainly be attributed to the continued adoption of EW’s life-saving technologies all over the world. Gross profit during the quarter came in at $895.4 million, up a marginal 0.8% year over year. Adjusted gross margin contracted 50 bps on a year over year basis, owing to negative impact of foreign exchange and expenses incurred associated with reacting to COVID-19. Operating income in 4QFY20 stood at $351.4 million, up from $310.8 million reported in the year-ago quarter.
4QFY20 Key Highlights (Source: Company Reports)
Segmental Highlights: Revenues from global sales in the TAVR product group went up by 1.8% year over year and came in at $776.2 million. In 4QFY20, sales from TMTT stood at $13.1 million, skyrocketing 83.6% on pcp. The company remained on track to gain from robust adoption of the PASCAL leaflet repair system in Europe. Sales from Surgical Structural Heart segment during the quarter decreased slightly by 0.5% and stood at $204.2 million, owing to increased number inflow of COVID-19 patients in hospitals, thus restricting surgical valve procedures. Lastly, sales from Critical Care stood at $198.2 million during the quarter, marginally down by 0.6% on a year over year basis, due to a decline in HemoSphere orders in the United States. However, strong sales of TruWave disposable pressure monitoring devices used in the ICU in the United States and Europe were key positives.
Segmental Details (Source: Company Reports)
Key Metrics, Liquidity & Balance Sheet Details: The company exited the FY20 with a cash balance of $1.183 billion, up from the prior year figure of $1.179 billion. Long-term debt at the end of the period came in at just $595 million. Net cash flow from operating activities in FY20 stood at $400 million, up from $399 million reported in the year-ago period. Capital expenditure came in at $113 million in FY20, up from $71 million reported in FY19. We opine that an increase in cash flow will facilitate it to pay off debt commitments as well as it will provide higher compensation to shareholders.
In FY20, Gross, operating, EBITDA and net margins stood at 75.4%, 20.5%, 32.2% and 18.8%, higher than the industry median of 66.1%, 6%, 12.8% and 0.0%, respectively. In FY20, ROE stood at 18.9%, higher than the industry median of 0.9%. Debt to equity multiple in the same time span stood at 0.13x, lower than the FY19 figure of 0.14x.
Profitability and Leverage Profile (Source: Refinitiv, Thomson Reuters), Analysis by Kalkine Group
Top 10 Shareholders: The top 10 shareholders together form around 33.34% of the total shareholdings while the top 4 constitutes the maximum holding. The Vanguard Group, Inc. and BlackRock Institutional Trust Company, N.A. are holding a maximum stake in the company at 7.76% and 5.35%, respectively, as also highlighted in the chart below:
Data Source: Refinitiv, Thomson Reuters, Chart Created by Kalkine Group
Risk Analysis: The company expects a decline in HemoSphere orders from hospitals in the US, owing to COVID-19 led uncertainties. This, in turn, has limited capital spending, which is likely to weigh on the top-line. Moreover, gross margin contraction also does not augur well for EW. This, along with stiff competition in the cardiac devices market, adds to the woes. EW’s business, financial, and operating conditions highly depends on general economic conditions and spending powers of customers. If such circumstances worsen, it may negatively impact the overall financial performance of the company.
Outlook: For 1QFY21, the company expects adjusted EPS to be in the ambit of 43-50 cents. Top-line in 1QFY21 is expected to be between $1.1-$1.2 billion. For FY21, the company expects adjusted EPS between $2-$2.20 and sales to be in the range of $4.9-$5.3 billion. The company remains optimistic regarding the robust adoption of the KONECT aortic valve conduit and the INSPIRIS aortic surgical valve. Further, the higher demand for SAPIEN 3 Ultra platform looks promising. Continuous progress in TAVR procedure volumes on a global basis buoy optimism. Further, the company expects to ride on strong adoption of TruWave along with operating margin expansion. Despite the uncertainties led by virus outbreak, the company anticipates recording underlying sales growth in high-single digits for its Surgical Structural Heart business in FY21.
Valuation Methodology: P/E Multiple Based Relative Valuation (Illustrative)
Data Source: Refinitiv, Thomson Reuters, Analysis by Kalkine Group
*% Premium/(Discount) is based on our assessment of the company’s NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation: Over the last three months, the stock went down by ~3.5%. The stock made a 52-week low and high of $64.77 and $92.08, respectively. On the technical analysis front, the stock has a support level of ~$78.89 and a resistance level of ~$88.36. We have valued the stock using the P/E multiple based illustrative relative valuation method and arrived at a target price of an upside of low double-digit (in percentage terms). We believe that the company can trade at a slight premium as compared to its peer’s median, considering the higher demand of SAPIEN 3 Ultra platform, increase in cash flow, promising outlook, and decent 4QFY20 Key numbers. We have taken peers like ICU Medical Inc (NASDAQ: ICUI), ABIOMED Inc (NASDAQ: ABMD), to name a few. Considering the company’s decent 4QFY20 performance, geographical expansion, encouraging outlook, and liquidity position and valuation, we give a “Buy” recommendation on the stock at the closing price of $84.12, down by 1.51% on 7 April 2021.
.jpg)
EW Daily Technical Chart (Source: Refinitiv, Thomson Reuters)
Note: Investment decision should be made depending on the investors’ appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the Valuation has been achieved and subject to the factors discussed above.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine do not hold interests in any of the securities or other financial products covered on the Kalkine website.